AR076784A1 - Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico - Google Patents
Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasicoInfo
- Publication number
- AR076784A1 AR076784A1 ARP100101754A ARP100101754A AR076784A1 AR 076784 A1 AR076784 A1 AR 076784A1 AR P100101754 A ARP100101754 A AR P100101754A AR P100101754 A ARP100101754 A AR P100101754A AR 076784 A1 AR076784 A1 AR 076784A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- combination according
- inhibitor
- combination
- antineoplastic agent
- Prior art date
Links
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 title 1
- 108010056274 polo-like kinase 1 Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 2
- 230000002152 alkylating effect Effects 0.000 abstract 2
- 239000002256 antimetabolite Substances 0.000 abstract 2
- 239000003080 antimitotic agent Substances 0.000 abstract 2
- 239000000138 intercalating agent Substances 0.000 abstract 2
- 239000003207 proteasome inhibitor Substances 0.000 abstract 2
- 108010006654 Bleomycin Proteins 0.000 abstract 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 101710183280 Topoisomerase Proteins 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960001561 bleomycin Drugs 0.000 abstract 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicacion 1: Una combinacion caracterizada porque comprende (a) un compuesto de formula (1) y (b) uno o más agentes antineoplásicos seleccionados del grupo consistente en un agente antimetabolito, un agente alquilante o de tipo alquilante, un agente intercalador, un inhibidor de topoisomerasa f o 11, un agente antimitotico, un inhibidor de quinasa, un inhibidor del proteasoma y un anticuerpo que inhibe un factor de crecimiento o su receptor, donde los ingredientes activos de la combinacion están presentes en cada caso en forma libre o en la forma de una sal farmacéuticamente aceptable o cualquier hidrato o solvato de los mismos. Reivindicacion 3: La combinacion de acuerdo con la reivindicacion 2, caracterizada porque el agente antimetabolito es gemcitabina o citarabina. Reivindicacion 6: La combinacion de acuerdo con la reivindicacion 1, caracterizada porque el agente intercalador es bleomicina. Reivindicacion 10: La combinacion de acuerdo con la reivindicacion 9, caracterizada porque el inhibidor de topoisomerasa II es doxorrubicina. Reivindicacion 12: La combinacion de acuerdo con la reivindicacion 11, caracterizada porque el agente antimitotico es paclitaxel. Reivindicacion 15: La combinacion de acuerdo con la reivindicacion 1, caracterizada porque el inhibidor del proteasoma es bortezomib. Reivindicacion 21: Una combinacion de acuerdo con la reivindicacion 1 o una composicion farmacéutica de acuerdo con la reivindicacion 18, caracterizada porque se usa para tratar o retardar el avance de un trastorno proliferativo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09161111 | 2009-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076784A1 true AR076784A1 (es) | 2011-07-06 |
Family
ID=42806010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101754A AR076784A1 (es) | 2009-05-26 | 2010-05-20 | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8927530B2 (es) |
| EP (1) | EP2435041B1 (es) |
| JP (1) | JP5785157B2 (es) |
| AR (1) | AR076784A1 (es) |
| ES (1) | ES2617689T3 (es) |
| TW (1) | TW201107327A (es) |
| WO (1) | WO2010136394A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5400791B2 (ja) * | 2007-12-04 | 2014-01-29 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用 |
| WO2011012534A1 (en) * | 2009-07-29 | 2011-02-03 | Nerviano Medical Sciences S.R.L. | Plk inhibitor salts |
| CN103339134B (zh) * | 2011-01-26 | 2015-12-23 | 内尔维阿诺医学科学有限公司 | 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用 |
| EP2668188B1 (en) * | 2011-01-26 | 2016-05-18 | Nerviano Medical Sciences S.r.l. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
| US20190381043A1 (en) | 2018-06-13 | 2019-12-19 | King Faisal Specialist Hospital & Research Centre | Method of Treatment of Cancer |
| JP7541974B2 (ja) | 2018-08-26 | 2024-08-29 | カーディフ・オンコロジー・インコーポレイテッド | Ｐｌｋ１標的のリン酸化状態及びｐｌｋ１阻害剤を用いた癌の治療 |
| US20220143021A1 (en) * | 2019-02-25 | 2022-05-12 | Cardiff Oncology, Inc. | Onvansertib for inhibiting non-adrenergic contraction of smooth muscle and prostate cell proliferation |
| EP3946313A4 (en) * | 2019-03-28 | 2022-12-07 | Cardiff Oncology, Inc. | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER |
| EP3911654A4 (en) | 2020-03-27 | 2022-05-11 | Uppthera | PLK1 SELECTIVE DEGRADATION-INDUCING COMPOUND |
| US11957677B2 (en) | 2021-10-15 | 2024-04-16 | Cardiff Oncology, Inc. | Cancer treatment using FGFR inhibitors and PLK1 inhibitors |
| EP4479042A1 (en) * | 2022-02-18 | 2024-12-25 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
| US20250215101A1 (en) | 2022-04-08 | 2025-07-03 | Inhibrx Biosciences, Inc. | DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy |
| EP4531847A4 (en) * | 2022-05-31 | 2025-12-24 | Cardiff Oncology Inc | CANCER TREATMENT USING TOPOISOMERASE I INHIBITORS AND PLK1 INHIBITORS |
| US20250057847A1 (en) | 2022-09-11 | 2025-02-20 | Cardiff Oncology, Inc. | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE330600T1 (de) * | 2000-01-26 | 2006-07-15 | Schering Corp | Kombinationspräparat zur krebstherapie |
| WO2004103344A1 (en) * | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
| US7482354B2 (en) * | 2003-05-22 | 2009-01-27 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| KR101512284B1 (ko) * | 2006-12-21 | 2015-04-15 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 치환된 피라졸로-퀴나졸린 유도체, 이의 제조방법, 및 키나제 억제제로서의 이의 용도 |
-
2010
- 2010-05-20 AR ARP100101754A patent/AR076784A1/es unknown
- 2010-05-21 ES ES10723967.5T patent/ES2617689T3/es active Active
- 2010-05-21 US US13/321,024 patent/US8927530B2/en active Active
- 2010-05-21 WO PCT/EP2010/057027 patent/WO2010136394A1/en not_active Ceased
- 2010-05-21 JP JP2012512317A patent/JP5785157B2/ja active Active
- 2010-05-21 EP EP10723967.5A patent/EP2435041B1/en active Active
- 2010-05-24 TW TW099116481A patent/TW201107327A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201107327A (en) | 2011-03-01 |
| EP2435041A1 (en) | 2012-04-04 |
| JP2012528099A (ja) | 2012-11-12 |
| JP5785157B2 (ja) | 2015-09-24 |
| WO2010136394A1 (en) | 2010-12-02 |
| US20120114641A1 (en) | 2012-05-10 |
| US8927530B2 (en) | 2015-01-06 |
| CN102448454A (zh) | 2012-05-09 |
| ES2617689T3 (es) | 2017-06-19 |
| EP2435041B1 (en) | 2016-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076784A1 (es) | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico | |
| CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| SV2018005663A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| SV2018005680A (es) | Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer | |
| AR079049A1 (es) | Combinacion terapeutica que comprende un inhibidor de cdc7 y un agente antineoplasico | |
| CO6160236A2 (es) | Inhibidor de quinasa | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| AR077629A1 (es) | Mimetico de smac | |
| MX394252B (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| CL2016003329A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CL2009000085A1 (es) | Compuestos derivados de sulfonamida sustituida, modulares de receptores de bradiquinina; proceso para su preparacion; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| CR20190144A (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
| CL2019002527A1 (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer. | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| CO6420321A2 (es) | Un derivado de cianopirimidina novedoso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |